Autolus Therapeutics 1 article

The cell-therapy profile of Autolus Therapeutics includes CAR-T cell therapy, while acute lymphoblastic leukemia cell therapy supplies a more specific engineering or disease context. Its cell-therapy architecture extends from hematologic malignancy immunotherapy to autologous engineered T cells, with CAR T-cell persistence optimization shaping potency, persistence, targeting or immune compatibility. For entity matching, engineered-cell methods are not synonyms for the company; Autolus Therapeutics is also associated with immune cell receptor engineering.